Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers of treatment outcome, we assessed NAAs in serial samples from SCLC patients treated with chemoimmunotherapy compared to chemotherapy alone. We eval...

Full description

Bibliographic Details
Main Authors: M. Hardy-Werbin, O. Arpí, A. Taus, P. Rocha, D. Joseph-Pietras, L. Nolan, S. Danson, R. Griffiths, M. Lopez-Botet, A. Rovira, J. Albanell, C. H. Ottensmeier, E. Arriola
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
anti-hu
anti-yo
autoantibodies
anti-sox-1
ipilimumab
paraneoplastic syndrome
small cell lung cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1395125

Internet

http://dx.doi.org/10.1080/2162402X.2017.1395125

Similar Items